

Patent Claims

5

1. Utilisation of 5' substituted nucleosides in combination with at least one cytostatic agent for producing a drug for preventing or reducing the formation of resistance in cytostatic treatment.

10

2. Utilisation according to claim 1, characterised in that (E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU) and/or its metabolites are used as a nucleoside.

15.

3. Utilisation according to claim 2, characterised in that (E)-5(2-Bromovinyl)-uracyl (BVU) is used as a metabolite.

20

4. Utilisation according to claim 1, characterised in that (E)-5-(2-bromovinyl)-1- β -D-arabinofuranosyluracil and/or its metabolites are used as a nucleoside.

25

5. Utilisation according to claim 1,

characterised in that (E)-5-(2-bromovinyl)-2'-deoxy-4'-thiouridine and/or its metabolites are used as a nucleoside.

5 6. Utilisation according to claim 1,
characterised in that 5-iodo-2'-deoxycytidine and/or its metabolites are used as a nucleoside.

7. Utilisation according to claim 1,
10 characterised in that 5-iodo-2'-deoxyuridine and/or its metabolites are used as a nucleoside.

8. Utilisation according to claim 1,
characterised in that 2'-Deoxy-5-trifluoromethyluridine
15 and/or its metabolites are used as a nucleoside.

9. Drug, containing 5' substituted nucleosides,
according to at least one of claims 1 to 8, in a quantity
from which there results a concentration of 0.02 µg/ml to
20 10 µg/ml in the blood, at least one cytostatic agent and
conventional carrier and auxiliary materials.

10. Drug according to claim 9,
characterised in that the nucleosides are contained in a
25 quantity from which a concentration of 0.05 µg/ml to 5
µg/ml results in the blood.

11. Drug according to claim 9 or 10,
characterised in that the cytostatic agents are selected
from alkaloids, alkylating agents, anti-metabolites,
5 antibiotics or cisplatin.

10

15

20

25